EMERGENT BIOSOLUTIONS INC. Net Income
EMERGENT BIOSOLUTIONS INC. (EBS) reported Net Income of -$180.20 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Net Income
us-gaap:NetIncomeLoss · last filed 2026-08-06
- EMERGENT BIOSOLUTIONS INC. net income (loss) attributable to parent for the quarter ending 2026-06-30 was -$180.20M.
- EMERGENT BIOSOLUTIONS INC. net income (loss) attributable to parent for the quarter ending 2026-03-31 was $6.80M, a 90.00% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. net income (loss) attributable to parent for the quarter ending 2025-12-31 was -$54.60M.
- EMERGENT BIOSOLUTIONS INC. net income (loss) attributable to parent for the quarter ending 2025-09-30 was $51.20M, a 55.40% decline year-over-year.
- EMERGENT BIOSOLUTIONS INC. net income (loss) attributable to parent for fiscal 2025 was $52.60M.
- EMERGENT BIOSOLUTIONS INC. net income (loss) attributable to parent for fiscal 2024 was -$190.60M.
- EMERGENT BIOSOLUTIONS INC. net income (loss) attributable to parent for fiscal 2023 was -$760.50M.
- EMERGENT BIOSOLUTIONS INC. net income (loss) attributable to parent for fiscal 2022 was -$211.60M, a 196.40% decline from fiscal 2021.
| Period end | Net Income (Loss) Attributable to Parent 3 month | Net Income (Loss) Attributable to Parent 3 month as first filed | Net Income (Loss) Attributable to Parent 6 month | Net Income (Loss) Attributable to Parent 6 month as first filed | Net Income (Loss) Attributable to Parent 9 month | Net Income (Loss) Attributable to Parent 9 month as first filed | Net Income (Loss) Attributable to Parent 12 month | Net Income (Loss) Attributable to Parent 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | -$180.20M 10-Q · filed 2026-08-06 | -$173.40M 10-Q · filed 2026-08-06 | -$228.00M derived: sum of 3 quarters · filed 2026-08-06 | -$176.80M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2026-03-31 | $6.80M 10-Q · filed 2026-08-06 | -$47.80M derived: sum of 2 quarters · filed 2026-08-06 | $3.40M derived: sum of 3 quarters · filed 2026-08-06 | -$8.60M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-12-31 | -$54.60M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$3.40M derived: sum of 2 quarters · filed 2026-02-27 | -$15.40M derived: sum of 3 quarters · filed 2026-08-06 | $52.60M 10-K · filed 2026-02-27 | ||||
| 2025-09-30 | $51.20M 10-Q · filed 2025-10-30 | $39.20M derived: sum of 2 quarters · filed 2026-08-06 | $107.20M 10-Q · filed 2025-10-30 | $75.90M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-06-30 | -$12.00M 10-Q · filed 2026-08-06 | $56.00M 10-Q · filed 2026-08-06 | $24.70M derived: sum of 3 quarters · filed 2026-08-06 | $139.50M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2025-03-31 | $68.00M 10-Q · filed 2026-08-06 | $36.70M derived: sum of 2 quarters · filed 2026-08-06 | $151.50M derived: sum of 3 quarters · filed 2026-08-06 | -$131.60M derived: sum of 4 quarters · filed 2026-08-06 | ||||
| 2024-12-31 | -$31.30M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | $83.50M derived: sum of 2 quarters · filed 2026-02-27 | -$199.60M derived: sum of 3 quarters · filed 2026-02-27 | -$190.60M 10-K · filed 2026-02-27 | ||||
| 2024-09-30 | $114.80M 10-Q · filed 2025-10-30 | -$168.30M derived: sum of 2 quarters · filed 2025-10-30 | -$159.30M 10-Q · filed 2025-10-30 | -$208.80M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-06-30 | -$283.10M 10-Q · filed 2025-10-30 | -$274.10M 10-Q · filed 2025-08-07 | -$323.60M derived: sum of 3 quarters · filed 2026-02-27 | -$587.00M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2024-03-31 | $9.00M 10-Q · filed 2025-10-30 | -$40.50M derived: sum of 2 quarters · filed 2026-02-27 | -$303.90M derived: sum of 3 quarters · filed 2026-02-27 | -$565.30M derived: sum of 4 quarters · filed 2026-02-27 | ||||
| 2023-12-31 | -$49.50M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-27 | -$312.90M derived: sum of 2 quarters · filed 2026-02-27 | -$574.30M derived: sum of 3 quarters · filed 2026-02-27 | -$760.50M 10-K · filed 2026-02-27 | ||||
| 2023-09-30 | -$263.40M 10-Q · filed 2024-11-07 | -$524.80M derived: sum of 2 quarters · filed 2024-11-07 | -$711.00M 10-Q · filed 2024-11-07 | -$778.00M derived: sum of 4 quarters · filed 2024-11-07 | ||||
| 2023-06-30 | -$261.40M 10-Q · filed 2024-11-07 | -$261.30M 10-Q · filed 2023-08-09 | -$447.60M 10-Q · filed 2024-08-07 | -$444.30M 10-Q · filed 2023-08-09 | -$514.60M derived: sum of 3 quarters · filed 2024-11-07 | -$601.70M derived: sum of 4 quarters · filed 2024-11-07 | ||
| 2023-03-31 | -$186.20M 10-Q · filed 2024-11-07 | -$183.00M 10-Q · filed 2023-05-10 | -$253.20M derived: sum of 2 quarters · filed 2024-11-07 | -$340.30M derived: sum of 3 quarters · filed 2024-11-07 | -$393.20M derived: sum of 4 quarters · filed 2024-11-07 | |||
| 2022-12-31 | -$67.00M 10-K/A · filed 2023-12-11 | -$154.10M derived: sum of 2 quarters · filed 2023-12-11 | -$207.00M derived: sum of 3 quarters · filed 2023-12-11 | -$211.60M 10-K · filed 2025-03-04 | -$223.80M 10-K · filed 2023-03-01 | |||
| 2022-09-30 | -$87.10M 10-K/A · filed 2023-12-11 | -$75.70M 10-Q · filed 2022-11-09 | -$140.00M derived: sum of 2 quarters · filed 2023-12-11 | -$144.60M 10-Q · filed 2023-12-11 | -$135.80M 10-Q · filed 2022-11-09 | $48.50M derived: sum of 4 quarters · filed 2023-12-11 | ||
| 2022-06-30 | -$52.90M 10-K/A · filed 2023-12-11 | -$56.40M 10-Q · filed 2022-08-02 | -$60.10M 10-Q · filed 2023-08-09 | $135.60M derived: sum of 3 quarters · filed 2023-12-11 | $95.20M derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2022-03-31 | -$4.60M 10-K/A · filed 2023-12-11 | -$3.70M 10-Q · filed 2022-04-29 | $188.50M derived: sum of 2 quarters · filed 2023-12-11 | $148.10M derived: sum of 3 quarters · filed 2023-12-11 | $147.60M derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2021-12-31 | $193.10M 10-K/A · filed 2023-12-11 | $152.70M derived: sum of 2 quarters · filed 2023-12-11 | $152.20M derived: sum of 3 quarters · filed 2023-12-11 | $219.50M 10-K · filed 2024-03-08 | $230.90M 10-K · filed 2022-02-25 | |||
| 2021-09-30 | -$40.40M 10-K/A · filed 2023-12-11 | -$32.70M 10-Q · filed 2021-11-05 | -$40.90M derived: sum of 2 quarters · filed 2023-12-11 | $41.60M 10-Q · filed 2022-11-09 | $211.80M derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2021-06-30 | -$500.00K 10-K/A · filed 2023-12-11 | $4.60M 10-Q · filed 2021-07-30 | $74.30M 10-Q · filed 2022-08-02 | $252.20M derived: sum of 3 quarters · filed 2023-12-11 | $291.70M derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2021-03-31 | $67.30M 10-K/A · filed 2023-12-11 | $69.70M 10-Q · filed 2021-04-30 | $252.70M derived: sum of 2 quarters · filed 2023-12-11 | $292.20M derived: sum of 3 quarters · filed 2023-12-11 | $384.90M derived: sum of 4 quarters · filed 2023-12-11 | |||
| 2020-12-31 | $185.40M 10-K · filed 2021-02-19 | $224.90M derived: sum of 2 quarters · filed 2021-11-05 | $317.60M derived: sum of 3 quarters · filed 2021-11-05 | $305.80M 10-K/A · filed 2023-12-11 | $305.10M 10-K · filed 2021-02-19 | |||
| 2020-09-30 | $39.50M 10-Q · filed 2021-11-05 | $132.20M derived: sum of 2 quarters · filed 2021-11-05 | $119.70M 10-Q · filed 2021-11-05 | $166.60M derived: sum of 4 quarters · filed 2021-11-05 | ||||
| 2020-06-30 | $92.70M 10-Q · filed 2021-07-30 | $80.20M 10-Q · filed 2021-07-30 | $127.10M derived: sum of 3 quarters · filed 2021-07-30 | $170.30M derived: sum of 4 quarters · filed 2021-07-30 | ||||
| 2020-03-31 | -$12.50M 10-Q · filed 2021-04-30 | $34.40M derived: sum of 2 quarters · filed 2021-04-30 | $77.60M derived: sum of 3 quarters · filed 2021-04-30 | $68.10M derived: sum of 4 quarters · filed 2021-04-30 | ||||
| 2019-12-31 | $46.90M 10-K · filed 2021-02-19 | $90.10M derived: sum of 2 quarters · filed 2021-02-19 | $80.60M derived: sum of 3 quarters · filed 2021-02-19 | $54.50M 10-K · filed 2022-02-25 | ||||
| 2019-09-30 | $43.20M 10-K · filed 2021-02-19 | $33.70M derived: sum of 2 quarters · filed 2021-02-19 | $7.60M 10-Q · filed 2020-11-06 | $4.20M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-06-30 | -$9.50M 10-K · filed 2021-02-19 | -$35.60M 10-Q · filed 2020-07-31 | -$39.00M derived: sum of 3 quarters · filed 2021-02-19 | -$18.10M derived: sum of 4 quarters · filed 2021-02-19 | ||||
| 2019-03-31 | -$26.10M 10-K · filed 2021-02-19 | -$26.00M 10-Q · filed 2019-05-08 | -$29.50M derived: sum of 2 quarters · filed 2021-02-19 | -$8.60M derived: sum of 3 quarters · filed 2021-02-19 | $41.50M derived: sum of 4 quarters · filed 2021-02-19 | |||
| 2018-12-31 | -$3.40M 10-K · filed 2020-02-25 | $17.50M derived: sum of 2 quarters · filed 2020-02-25 | $67.60M derived: sum of 3 quarters · filed 2020-02-25 | $62.70M 10-K · filed 2021-02-19 | ||||
| 2018-09-30 | $20.90M 10-K · filed 2020-02-25 | $20.95M 10-Q · filed 2018-11-02 | $71.00M derived: sum of 2 quarters · filed 2020-02-25 | $66.20M 10-Q · filed 2019-11-07 | $66.18M 10-Q · filed 2018-11-02 | $100.05M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-06-30 | $50.10M 10-K · filed 2020-02-25 | $50.14M 10-Q · filed 2018-08-03 | $45.20M 10-Q · filed 2019-08-02 | $45.24M 10-Q · filed 2018-08-03 | $79.15M derived: sum of 3 quarters · filed 2020-02-25 | $112.70M derived: sum of 4 quarters · filed 2020-02-25 | ||
| 2018-03-31 | -$4.90M 10-K · filed 2020-02-25 | -$4.91M 10-Q · filed 2018-05-04 | $29.05M derived: sum of 2 quarters · filed 2020-02-25 | $62.60M derived: sum of 3 quarters · filed 2020-02-25 | $67.22M derived: sum of 4 quarters · filed 2020-02-25 | |||
| 2017-12-31 | $33.95M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-25 | $67.50M derived: sum of 2 quarters · filed 2020-02-25 | $72.11M derived: sum of 3 quarters · filed 2020-02-25 | $82.60M 10-K · filed 2020-02-25 | $82.59M 10-K · filed 2018-02-23 | |||
| 2017-09-30 | $33.55M 10-Q · filed 2018-11-02 | $38.17M derived: sum of 2 quarters · filed 2018-11-02 | $48.65M 10-Q · filed 2018-11-02 | $86.07M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-06-30 | $4.62M 10-Q · filed 2018-08-03 | $15.10M 10-Q · filed 2018-08-03 | $52.52M derived: sum of 3 quarters · filed 2019-02-22 | $73.86M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2017-03-31 | $10.48M 10-Q · filed 2018-05-04 | $47.90M derived: sum of 2 quarters · filed 2019-02-22 | $69.24M derived: sum of 3 quarters · filed 2019-02-22 | $58.29M derived: sum of 4 quarters · filed 2019-02-22 | ||||
| 2016-12-31 | $37.42M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-22 | $58.76M derived: sum of 2 quarters · filed 2019-02-22 | $47.81M derived: sum of 3 quarters · filed 2019-02-22 | $51.80M 10-K · filed 2019-02-22 | $51.78M 10-K · filed 2017-02-28 | |||
| 2016-09-30 | $21.34M 10-Q · filed 2017-11-03 | $10.39M derived: sum of 2 quarters · filed 2017-11-03 | $14.38M 10-Q · filed 2017-11-03 | $47.73M derived: sum of 4 quarters · filed 2017-11-03 | ||||
| 2016-06-30 | -$10.95M 10-Q · filed 2017-08-04 | -$6.96M 10-Q · filed 2017-08-04 | $26.39M derived: sum of 3 quarters · filed 2017-08-04 | $63.33M derived: sum of 4 quarters · filed 2017-08-04 | ||||
| 2016-03-31 | $3.99M 10-Q · filed 2017-05-05 | $37.34M derived: sum of 2 quarters · filed 2017-05-05 | $74.28M derived: sum of 3 quarters · filed 2017-05-05 | $88.38M derived: sum of 4 quarters · filed 2017-05-05 | ||||
| 2015-12-31 | $33.35M 10-K · filed 2016-02-29 | $70.29M derived: sum of 2 quarters · filed 2016-11-09 | $84.39M derived: sum of 3 quarters · filed 2016-11-09 | $62.87M 10-K · filed 2018-02-23 | ||||
| 2015-09-30 | $36.94M 10-Q · filed 2016-11-09 | $36.94M 10-Q · filed 2015-11-06 | $51.04M derived: sum of 2 quarters · filed 2016-11-09 | $29.52M 10-Q · filed 2016-11-09 | $59.64M derived: sum of 4 quarters · filed 2016-11-09 | |||
| 2015-06-30 | $14.10M 10-Q · filed 2016-08-05 | -$7.42M 10-Q · filed 2016-08-05 | $22.70M derived: sum of 3 quarters · filed 2016-08-05 | $44.53M derived: sum of 4 quarters · filed 2016-08-05 | ||||
| 2015-03-31 | -$21.52M 10-Q · filed 2016-05-06 | $8.60M derived: sum of 2 quarters · filed 2016-05-06 | $30.43M derived: sum of 3 quarters · filed 2016-05-06 | $35.46M derived: sum of 4 quarters · filed 2016-05-06 | ||||
| 2014-12-31 | $30.12M 10-K · filed 2016-02-29 | $51.95M derived: sum of 2 quarters · filed 2016-02-29 | $56.98M derived: sum of 3 quarters · filed 2016-02-29 | $36.74M 10-K · filed 2017-02-28 | ||||
| 2014-09-30 | $21.83M 10-K · filed 2016-02-29 | $26.86M derived: sum of 2 quarters · filed 2016-02-29 | $6.63M 10-Q · filed 2015-11-06 | $21.85M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-06-30 | $5.03M 10-K · filed 2016-02-29 | -$15.21M 10-Q · filed 2015-08-06 | $15.00K derived: sum of 3 quarters · filed 2016-02-29 | $13.51M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2014-03-31 | -$20.24M 10-K · filed 2016-02-29 | -$5.01M derived: sum of 2 quarters · filed 2016-02-29 | $8.48M derived: sum of 3 quarters · filed 2016-02-29 | $18.96M derived: sum of 4 quarters · filed 2016-02-29 | ||||
| 2013-12-31 | $15.22M 10-K · filed 2015-03-09 | $28.71M derived: sum of 2 quarters · filed 2015-03-09 | $39.20M derived: sum of 3 quarters · filed 2015-03-09 | $31.14M 10-K · filed 2016-02-29 | ||||
| 2013-09-30 | $13.49M 10-K · filed 2015-03-09 | $23.98M derived: sum of 2 quarters · filed 2015-03-09 | $15.91M 10-Q · filed 2014-11-10 | $32.02M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-06-30 | $10.48M 10-K · filed 2015-03-09 | $2.42M 10-Q · filed 2014-08-08 | $18.53M derived: sum of 3 quarters · filed 2015-03-09 | $25.14M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2013-03-31 | -$8.06M 10-K · filed 2015-03-09 | $8.04M derived: sum of 2 quarters · filed 2015-03-09 | $14.66M derived: sum of 3 quarters · filed 2015-03-09 | $22.29M derived: sum of 4 quarters · filed 2015-03-09 | ||||
| 2012-12-31 | $16.10M 10-K · filed 2014-03-10 | $22.72M derived: sum of 2 quarters · filed 2014-03-10 | $30.35M derived: sum of 3 quarters · filed 2014-03-10 | $23.52M 10-K · filed 2015-03-09 | ||||
| 2012-09-30 | $6.62M 10-K · filed 2014-03-10 | $14.25M derived: sum of 2 quarters · filed 2014-03-10 | $7.42M 10-Q · filed 2013-11-08 | $36.08M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-06-30 | $7.63M 10-K · filed 2014-03-10 | $800.00K 10-Q · filed 2013-08-06 | $29.46M derived: sum of 3 quarters · filed 2014-03-10 | $31.01M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2012-03-31 | -$6.83M 10-K · filed 2014-03-10 | $21.83M derived: sum of 2 quarters · filed 2014-03-10 | $23.38M derived: sum of 3 quarters · filed 2014-03-10 | $37.59M derived: sum of 4 quarters · filed 2014-03-10 | ||||
| 2011-12-31 | $28.66M 10-K · filed 2013-03-08 | $30.21M derived: sum of 2 quarters · filed 2013-03-08 | $44.42M derived: sum of 3 quarters · filed 2013-03-08 | $23.02M 10-K · filed 2014-03-10 | ||||
| 2011-09-30 | $1.55M 10-K · filed 2013-03-08 | $15.76M derived: sum of 2 quarters · filed 2013-03-08 | -$5.64M 10-Q · filed 2012-11-01 | $20.61M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2011-06-30 | $14.21M 10-K · filed 2013-03-08 | -$7.19M 10-Q · filed 2012-08-03 | $19.06M derived: sum of 3 quarters · filed 2013-03-08 | $32.18M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2011-03-31 | -$21.40M 10-K · filed 2013-03-08 | $4.85M derived: sum of 2 quarters · filed 2013-03-08 | $17.97M derived: sum of 3 quarters · filed 2013-03-08 | $27.78M derived: sum of 4 quarters · filed 2013-03-08 | ||||
| 2010-12-31 | $26.25M derived: 10-K 12 month − 10-Q 9 month · filed 2013-03-08 | $39.37M derived: sum of 2 quarters · filed 2013-03-08 | $49.17M derived: sum of 3 quarters · filed 2013-03-08 | $51.70M 10-K · filed 2013-03-08 | ||||
| 2010-09-30 | $13.12M 10-Q · filed 2011-11-04 | $22.93M derived: sum of 2 quarters · filed 2011-11-04 | $25.45M 10-Q · filed 2011-11-04 | |||||
| 2010-06-30 | $9.81M 10-Q · filed 2011-08-05 | $12.33M 10-Q · filed 2011-08-05 | ||||||
| 2009-12-31 | $31.14M 10-K · filed 2012-03-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |